Leveraging the Anti-Tumor Activity of the Immune System: Systemic Treatment for Advanced Non-Melanoma Skin Cancers

Target Audience
This activity is designed to meet the educational needs of global oncologists, dermatologists, Mohs surgeons, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.

Program Overview
This enduring activity will increase the target HCP’s understanding of new immune therapies and clinical trial data for treating patients with advanced NMSCs; ability to identify and manage side effects associated with new systemic therapies for treating patients with advanced BCC; and ability to coordinate care and improve outcomes for patients with advanced NMSCs failing or not amenable to surgery or radiation.

Learning Objectives
After participating in this program, participants will be better able to:

Evaluate recent immune therapy clinical trials data in the treatment of patients with metastatic or locally advanced non-melanoma skin cancers
Describe the recognition and management of treatment related adverse events associated with immune checkpoint inhibitor therapy in patients with non-melanoma skin cancers
Examine the communication, processes and tools that support a multidisciplinary team approach in the management of patients with non-melanoma skin cancers